Abstract
The group of young ADHD patients with confirmed DAT' polymorfism was studied to describe 1H MRS metabolic profile and grey matter thickness association with pharmacological treatment. Subjects and Methods 30 ADHD patients from DAT' (10/10) positive families (mean age 15.6 +- 2.5 y/o, 3 girls) with the history of at least 5-year treatment by methylphenidate or atomoxetine underwent clinical and MRI+MRS examination at least 3 weeks afterpharmacotherapy termination. 3o healthy controls (mean age 16.5 +- 1.8 y/o, 6 girls) were examined by the same clinical and MR protocols at 3T whole-body MR systém equipped with Tx/Rx head coil.
PRESS sequences with TR/TE = 5000/30 and 135 ms were used in the left and right putamen and surrounding area in basal ganglia with volume of interest of 11.2 ml. Metabolite concentrations were calculated using LCModel technique.
Results as the spectroscopic data from right and left hemispheres were not significantly different, they were pooled. No significant differences were found between patient and control groups in any parameter.
Grey matter thickness was found significantly higher in patients in prefrontal and occipital areas.